<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068363</url>
  </required_header>
  <id_info>
    <org_study_id>IBR/0006379</org_study_id>
    <nct_id>NCT04068363</nct_id>
  </id_info>
  <brief_title>Donor Gender Effect on Graft Function in Adult Egyptian Patients Undergoing Living Donor Liver Transplant</brief_title>
  <official_title>Donor Gender Effect on Graft Function in Adult Egyptian Patients Undergoing Living Donor Liver Transplant: A Single Centre Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver transplantation (LT) represents the gold-standard therapy for the treatment in case of&#xD;
      dreadful liver pathologies . It is thus a main concern to optimize the results in terms of&#xD;
      post-LT survivals. The effect of gender match on post-transplant outcome is still debatable.&#xD;
      Hormonal , and size difference between female and male may be proposed to affect the post&#xD;
      transplant outcome . The aim of this study is to evaluate the effect of donor-recipient&#xD;
      gender mismatch on survival rates&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2019</start_date>
  <completion_date type="Anticipated">June 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>2 years survival post liver transplant.</measure>
    <time_frame>3 months</time_frame>
    <description>The primary outcome will be survival at 2 years post liver transplant</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Donor to Recipient Gender Mismatch in LDLT</condition>
  <arm_group>
    <arm_group_label>Matched group</arm_group_label>
    <description>Same sex of both donor and recipient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mismatched group</arm_group_label>
    <description>Sex mismatch between donor and recipient, subgroups might be added</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non interventional</intervention_name>
    <description>non interventional study</description>
    <arm_group_label>Matched group</arm_group_label>
    <arm_group_label>Mismatched group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Intraoperatively, Both standard anesthetic and piggyback liver transplant for hepatic&#xD;
        transplantation will be performed by the same anesthesia and surgical team . Intraoperative&#xD;
        hemodynamics (MAP and HR), graft weight to recipient weight ratio (GWRWR), blood products&#xD;
        transfused and intraoperative adverse events will be recorded. At the end of surgery&#xD;
        patients will be transferred to the ICU where they will be monitored and will receive the&#xD;
        standard protocol for postoperative management after liver transplantation.&#xD;
&#xD;
        - Recipients will be divided into two groups ( matched and mismatched) and will be&#xD;
        subdivided based on the following variables: recipient age, MELD score, intraoperative&#xD;
        packed red blood cells (PRBC) and fresh frozen plasma (FFP) transfusions, duration of cold&#xD;
        ischemia. These subgroups will be compared with respect to 2-year graft survival separately&#xD;
        in recipients of sex matched and mismatched transplantation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult Egyptian Patients &gt;18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal.&#xD;
&#xD;
          -  Patients who underwent re-transplantation before discharge from the ICU after the&#xD;
             first liver transplant.&#xD;
&#xD;
          -  Intraoperative cardiac arrest or immediately postoperative cardiac arrest within the&#xD;
             first 6 hours postoperative.&#xD;
&#xD;
          -  Massive blood loss.&#xD;
&#xD;
          -  Pre-existing renal failure requiring hemodialysis or continuous hemofiltration.&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hanaa A ELGENDY</last_name>
    <phone>+201001029544</phone>
    <email>hanaa.elgendy@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hanaa El Gendy</name>
      <address>
        <city>Cairo</city>
        <state>Ain Shams University Specialized Hospital</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanaa Abdalla ElGendy</last_name>
      <phone>0100 102 9544</phone>
      <email>Hanaa.elgendy@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Hanaa Mohamed Abdallah ElGendy MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

